AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03181334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch III
Description: FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.~Participants are assigned to the following intervention:~Branch III: Invitation letter to participate in free CRC screening, requesting they return the kit within 3-weeks.
Study NCT03181334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch IV
Description: FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch IV: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher incentive or within 3-weeks for a lower (half of the higher) incentive.
Study NCT03181334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Branch V
Description: FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.~Participants are assigned to the following intervention:~Branch V: Invitation letter to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as lower Branch IV) or within 3-weeks for a lower (half of lower Branch IV) incentive.
Study NCT00895167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Description: one oral dose of 12 caplets = 12 g curcumin
Study NCT00601458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pregabalin
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Study NCT00601458 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naproxen sodium
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
Study NCT01922986 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: 20 minutes of sham rTMS stimulation
Study NCT01922986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional stroke therapy
Description: conventional stroke therapy consisting of exercises and physical training
Study NCT01922986 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional stroke therapy
Description: conventional stroke therapy consisting of exercises and physical training
Study NCT02302586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block (TPVB)
Description: Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
Study NCT02302586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Patient Controlled Analgesia (IV PCA)
Description: IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
Study NCT02778542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Pill Bottle
Description: Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
Study NCT02778542 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bidirectional Text Messaging
Description: Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
Study NCT01469936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PERMEAPROTECT
Description: Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.~Duration : 5 weeks +/- 1 week.~Dosage :~* First Week of intervention : 1/2 stick per day~* Second to 5th Week : 1 stick per day
Study NCT01469936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Duration : 5 weeks +/- 1 week.~Dosage:~* First Week : 1/2 stick per day~* Second to 5th Week : 1 stick per day
Study NCT03071315 — intervention group
Intervention type: OTHER
Intervention: CCT
Description: CCT focuses on behavioral approach, mainly punitive punishment measures.
Study NCT03071315 — intervention group
Intervention type: OTHER
Intervention: MMT
Description: MMT is a combination of pharmaceutical and behavioral intervention.
Study NCT00989846 — intervention group
Intervention type: OTHER
Intervention: biomarker
Description: measuring serum-biomarkers
Study NCT03774043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Patients will breath 9%-11% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
Study NCT03774043 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Acute Intermittent Hypoxia
Description: Patients will breath 21% oxigen for 1.5 minutes interspersed with 1.5 minutes of room air, 15 times for a total of 45 minutes.
Study NCT02922816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant (FMT)
Description: The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
Study NCT02922816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bowel preparation
Description: Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
Study NCT02922816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bowel preparation
Description: Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
Study NCT05152992 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing visual stimuli and electrical stimulation of the brain
Description: View emotionally evocative videos and undergo stimulation of brain regions involved in emotion. In a 20-minute block (5 total blocks), eighteen 30-second movie clips will be used to elicit different categories of emotions (sadness, fear, disgust, awe, affection, and amusement). Additionally, each hub of the emotion network will be stimulated to identify areas that generate similar emotional states as those elicited by the videos. Each stimulation trial consists of 3 minutes of 1-3 mA, 50 Hz, 100 us pulse-width stimulation.
Study NCT00130546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel-eluting TAXUS(TM)
Description: TAXUS(TM) Paclitaxel-eluting stent
Study NCT00130546 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus eluting Cypher Select(TM)
Description: Sirolimus eluting Cypher Select(TM) stent
Study NCT01087359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study NCT01087359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin
Description: 100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
Study NCT02922816 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Stool or perirectal swab sampling
Description: Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
Study NCT02922816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stool or perirectal swab sampling
Description: Stool or perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
Study NCT02922816 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting
Description: In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
Study NCT06531187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence-Based Practice (EBP) Teaching
Description: The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP).
Study NCT06531187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Practice (EBP) Teaching
Description: The experimental group will receive a 4-hour gamified instructional design course focused on teaching Evidence-Based Practice (EBP), based on the Octalysis Framework of game elements proposed by Chou (2019).~The active comparator group will participate in 4-hour conventional small group discussions focused on teaching Evidence-Based Practice (EBP).
Study NCT01814046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
Study NCT01814046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study NCT01814046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m\^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
Study NCT01814046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Young Tumor Infiltrating Lymphocytes (TIL)
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
Study NCT00601458 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
Study NCT01815515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DCFBC
Description: 18F-DCFBC is a radiofluorinated small-molecule inhibitor of prostate-specific membrane antigen (PSMA).~A bolus of 10 mCi (370 MBq) \[9-11 mCi (333-407 MBq)\] of 18F-DCFBC will be injected into the IV line by slow IV push.
Study NCT01218568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin plus lactulose
Description: Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
Study NCT01218568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Lactulose 30-60 ml in two or three divided doses.
Study NCT00380497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-Lyte®
Study NCT00380497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pico-Salax®
Study NCT03406572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFHO Group
Description: * Common name: humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases~* Brand name: Airvo 2
Study NCT03406572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard O2
Description: Standard oxygen therapy
Study NCT02670837 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellutome Epidermal Harvesting System
Study NCT04023344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog Mix25
Description: Subcutaneus injections Humalog® Mix 25 twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study NCT04023344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Biphasic 25
Description: Subcutaneus injections Insulin Lispro Biphasic 25 (Geropharm) twice daily during 4 weeks of glucose-level based dose titration, 24 weeks of treatment with stable doses
Study NCT01866306 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV16UB
Description: RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
Study NCT05349994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended physiotherapy
Description: At admission to the surgical ward after ICU care, participants received an individual rehabilitation plan developed in collaboration with the participants and the ward-based physiotherapist. The rehabilitation plan included specified exercises for 1- 2 sessions of approximately 30 minutes a day. For example breathing exercises, practicing transfer in and out of bed and from sitting to standing, stairclimbing, and walking with or without walking aids.
Study NCT01200602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: megestrol acetate
Description: Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
Study NCT01200602 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clinical observation
Description: No treatment is given.
Study NCT03984097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-079
Description: TAK-079 subcutaneously.
Study NCT01866306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LABA
Description: Asthmatic participants were treated with LABA as part of their standard of care
Study NCT03984097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide orally.
Study NCT03984097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone orally.
Study NCT01404806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572 (dolutegravir)
Description: Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
Study NCT00623766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
Study NCT00623766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Betamethasone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
Study NCT00623766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Dexamethasone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
Study NCT00623766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Fludrocortisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
Study NCT00623766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroid: Hydrocortisone
Description: Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
Study NCT01001988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample for immunogenicity assessment
Study NCT01001988 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JE-CV administered in Study JEC02
Description: Participants received a single dose of JE-CV at 12 to 18 months of age in Study JEC02. No vaccination was administered in Study JEC05
Study NCT01288144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement initiative
Description: In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
Study NCT00912912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: 50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
Study NCT00191113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin
Description: 0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
Study NCT00191113 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Ethinyl estradiol
Description: escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
Study NCT00191113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol
Description: escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
Study NCT00191113 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Medroxyprogesterone acetate
Description: 10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
Study NCT00191113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Description: 10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
Study NCT01181960 — intervention group
Intervention type: DRUG
Intervention: Risperidone long acting injectable - New Starts
Description: Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
Study NCT01181960 — intervention group
Intervention type: DRUG
Intervention: Risperidone long acting injectable - Continuous Users
Description: Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
Study NCT01181960 — intervention group
Intervention type: DRUG
Intervention: Paliperidone Palmitate -New and Continuous Users
Description: Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
Study NCT01181960 — intervention group
Intervention type: DRUG
Intervention: Other Antipsychotics - New Starts
Description: Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
Study NCT01952210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nutritional consultation and exercise program
Description: The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
Study NCT01952210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: pre-CCRT education included self-care during CCRT and body weight maintenance
Study NCT05584592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intergrate early palliatuve care + Conventional chemotherapy
Description: Sixty patients with gastric and pancreatic cancer will be eligible, and 30 patients will be randomly assigned to the exercise therapy + high protein supplement group and 30 patients to the exercise therapy + placebo supplement group.
Study NCT05584592 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional chemotherapy
Description: patients to receive routine palliative care when they want it or when it is needed by health care providers. In other words, if a patient assigned to the control group desires palliative care, they can receive conventional palliative care.